Your browser doesn't support javascript.
loading
Pilot Multi-Omic Analysis of Human Bile from Benign and Malignant Biliary Strictures: A Machine-Learning Approach.
Urman, Jesús M; Herranz, José M; Uriarte, Iker; Rullán, María; Oyón, Daniel; González, Belén; Fernandez-Urién, Ignacio; Carrascosa, Juan; Bolado, Federico; Zabalza, Lucía; Arechederra, María; Alvarez-Sola, Gloria; Colyn, Leticia; Latasa, María U; Puchades-Carrasco, Leonor; Pineda-Lucena, Antonio; Iraburu, María J; Iruarrizaga-Lejarreta, Marta; Alonso, Cristina; Sangro, Bruno; Purroy, Ana; Gil, Isabel; Carmona, Lorena; Cubero, Francisco Javier; Martínez-Chantar, María L; Banales, Jesús M; Romero, Marta R; Macias, Rocio I R; Monte, Maria J; Marín, Jose J G; Vila, Juan J; Corrales, Fernando J; Berasain, Carmen; Fernández-Barrena, Maite G; Avila, Matías A.
Afiliación
  • Urman JM; Department of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.
  • Herranz JM; IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.
  • Uriarte I; National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Carlos III Health Institute, 28029 Madrid, Spain.
  • Rullán M; Program of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
  • Oyón D; National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Carlos III Health Institute, 28029 Madrid, Spain.
  • González B; Program of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
  • Fernandez-Urién I; Department of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.
  • Carrascosa J; Department of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.
  • Bolado F; Department of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.
  • Zabalza L; Department of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.
  • Arechederra M; IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.
  • Alvarez-Sola G; Department of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.
  • Colyn L; IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.
  • Latasa MU; Department of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.
  • Puchades-Carrasco L; Department of Gastroenterology and Hepatology, Navarra University Hospital Complex, 31008 Pamplona, Spain.
  • Pineda-Lucena A; IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.
  • Iraburu MJ; Program of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
  • Iruarrizaga-Lejarreta M; National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Carlos III Health Institute, 28029 Madrid, Spain.
  • Alonso C; Program of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
  • Sangro B; Program of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
  • Purroy A; Program of Hepatology, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
  • Gil I; Drug Discovery Unit, Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain.
  • Carmona L; Drug Discovery Unit, Instituto de Investigación Sanitaria La Fe, Hospital Universitario y Politécnico La Fe, 46026 Valencia, Spain.
  • Cubero FJ; Program of Molecular Therapeutics, Center for Applied Medical Research (CIMA), University of Navarra, 31008 Pamplona, Spain.
  • Martínez-Chantar ML; Department of Biochemistry and Genetics, School of Sciences; University of Navarra, 31008 Pamplona, Spain.
  • Banales JM; OWL Metabolomics, Bizkaia Technology Park, 48160 Derio, Spain.
  • Romero MR; OWL Metabolomics, Bizkaia Technology Park, 48160 Derio, Spain.
  • Macias RIR; IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.
  • Monte MJ; National Institute for the Study of Liver and Gastrointestinal Diseases, CIBERehd, Carlos III Health Institute, 28029 Madrid, Spain.
  • Marín JJG; Hepatology Unit, Department of Internal Medicine, University of Navarra Clinic, 31008 Pamplona, Spain.
  • Vila JJ; IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.
  • Corrales FJ; Navarrabiomed Biobank Unit, IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.
  • Berasain C; IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.
  • Fernández-Barrena MG; Navarrabiomed Biobank Unit, IdiSNA, Navarra Institute for Health Research, 31008 Pamplona, Spain.
  • Avila MA; Proteomics Unit, Centro Nacional de Biotecnología (CNB) Consejo Superior de Investigaciones Científicas (CSIC), 28049 Madrid, Spain.
Cancers (Basel) ; 12(6)2020 Jun 21.
Article en En | MEDLINE | ID: mdl-32575903
ABSTRACT
Cholangiocarcinoma (CCA) and pancreatic adenocarcinoma (PDAC) may lead to the development of extrahepatic obstructive cholestasis. However, biliary stenoses can also be caused by benign conditions, and the identification of their etiology still remains a clinical challenge. We performed metabolomic and proteomic analyses of bile from patients with benign (n = 36) and malignant conditions, CCA (n = 36) or PDAC (n = 57), undergoing endoscopic retrograde cholangiopancreatography with the aim of characterizing bile composition in biliopancreatic disease and identifying biomarkers for the differential diagnosis of biliary strictures. Comprehensive analyses of lipids, bile acids and small molecules were carried out using mass spectrometry (MS) and nuclear magnetic resonance spectroscopy (1H-NMR) in all patients. MS analysis of bile proteome was performed in five patients per group. We implemented artificial intelligence tools for the selection of biomarkers and algorithms with predictive capacity. Our machine-learning pipeline included the generation of synthetic data with properties of real data, the selection of potential biomarkers (metabolites or proteins) and their analysis with neural networks (NN). Selected biomarkers were then validated with real data. We identified panels of lipids (n = 10) and proteins (n = 5) that when analyzed with NN algorithms discriminated between patients with and without cancer with an unprecedented accuracy.
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: España

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Cancers (Basel) Año: 2020 Tipo del documento: Article País de afiliación: España